Arrhythmias and Sudden Death in Heart Failure

Japanese Circulation Journal

Volumn 61, Issue 9, 1997, Pages 727-740

  Stevenson, William G ^a   Sweeney, Michael O ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; MAGNESIUM; MILRINONE; POTASSIUM; SOTALOL;

ARTICLE; BRADYCARDIA; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; DEFIBRILLATOR; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; MAGNESIUM BLOOD LEVEL; MORTALITY; REENTRY TACHYCARDIA; SUDDEN DEATH; SURVIVAL RATE; SYNCOPE;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIAC OUTPUT, LOW; DEATH, SUDDEN, CARDIAC; HUMANS; TACHYCARDIA; VENTRICULAR DYSFUNCTION; VENTRICULAR FIBRILLATION;

EID: 0030845738     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.61.727     Document Type: Article

References (115)

1. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
2. CohnJ. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., DunkmanW. B., Loeb H., Wong M., Bhat G., Goldman S., Fletcher R. D., Doherty J., Hughes C. V., Carson P., Contron G., Shabetai R., Haakenson C.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
3. Fonorow G. C., Chelimsky-Fallickk C., Stevenson L. W., Luu M., Hamilton M. A., Moriguchi J. D., Tillisch J. H., Creaser J A., Albanese E.: Effect of direct vasodilation vs angiotensin-converting enzyme inhibition on mortality in advanced heart failure: The hy-c trial. J Am Coll Cardiol 1992; 19: 842-850.
4. Stevenson W. G., Stevenson L. W., Middledauff H. R., Fonarow G. C., Hamilton M. A., Woo M. A., Saxon L. A., Natterson P. D., Steimle A., Walden J. A., Tillisch J. H.: Improving survival for patients with advanced heart failure: A study of 737 consecutive patients. J Am Coll Cardiol 1995; 26: 1417-1423.
5. Stevenson W. G., Stevenson L. W., Middlekauff H. R., Saxon L. A.: Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993; 88: 2953-2961.
6. Cohn J. N., Joyhnson G. R., Shabetai R., Loeb H., Tristani F., Rector T., Smith R., Fletcher R.: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87: VI5-VI16.
7. Goldman S., Johnson G., Cohn J. N., Cintron G., Smith R., Francis G.: Mechanism of death in heart failure, The Vasodilator-Heart Failure Trials. Circulation 1993; 87: VI24-VI31.
8. Keogh A. M., Baron D. W., Hickie J.B.: Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65:903-908.
9. Doval H. C., Nul D. R., Grancelli H. O., Varini S. D., Soifer S., Corrado G., Dubner S., Scapin O., Perrone S. V.: Non-sustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. Circulation 1996; 94: 3198-3203.
10. Schoeller R., Andresen D., Büttner P., et al: First- or second-degree atrioventricular block as a risk factor in idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 71: 720-726.
11. Doval H. C., Nul D. R., Grancelli H. O., Perrone S. V., Bortman G. R., Curiel R.: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-498.
12. Nicklas J. M., McKenna W. J., Stewart R. A., Michelson J. K., Das S. K., Schork M. A., Krikler S. J., Quain L. A., Morady F., Pitt B.: Prospective double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016-1021.
13. Natterson P. D., Stevenson W. G., Saxon L. A., Middlekauff H. R., Stevenson L. W.: Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995; 129: 564-570.
14. Wang Y., Scheinman M. M., Chien W. W., Cohen T. J., Lesh M. D., Griffin J. C.: Patients with supraventricular tachycardia presenting with aborted sudden death: Incidence, mechanism and long-term follow-up. J Am Coll Cardiol 1991; 18: 1711-1719.
15. Stevenson W. G.: Ventricular tachycardia after myocardial infarction: From arrhythmia surgery to catheter ablation. J Cardiovasc Electrophysiol 1995; 6(Pt II): 942-950.
16. Wolfe C. L., Nibley C., Bhandari A., et al: Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543-1551.
17. Kendall M. J., Lynch K. P., Hjalmarson A., Kjekshus J.: β-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-367.
18. Schwartz P. K., La Rdvere T., Vanoli E.: Autonomic nervous system and sudden cardiac death: Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85: 177-191.
19. Martins J. B., Kim W., Marcus M. L.: Chronic hypertension and left ventricular hypertrophy facilitate induction of sustained ventricular tachycardia in dogs 3 h after left circumflex coronary occlusion. J Am Col Cardiol 1986; 14: 1365-1373.
20. Garan H., McGovern B. A., Canzanello V. J., McCauley J., Nodvarsson M., Harrington J. T., Madias N. E., Newell J. B., Ruskin J. N.: The effect of potassium ion depletion on postinfarction canine cardiac arrhythmias. Circulation 1988; 77: 696-704.
21. Blanck Z., Dhala A., Deshpande S., et al: Bundle branch reentrant ventricular tachycardia: Cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993; 4: 253-262.
22. Aronson R. S.: Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol 1991; 2: 249-261.
23. Li H. G., Jones D. L., Yee R., Klein G. J.: Electrophysiologic substrate associated with pacing-induced heart failure in dogs: Potential value of programmed stimulation in predicting sudden death. J Am Coll Cardiol 1992; 19: 444-449.
24. Tomaselli G. F., Beuckelmann D. J., Calkins H. G., Berger R. D., Kessler P. D., Lawrence J. H., Kass D., Feldman A. M., Marban E.: Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 1994; 90: 2534-2539.
25. Peter N. S., Green C. R., Poole-Wilson P. A., Severs N. J.: Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993; 88: 864-875.
26. Beuckelmann D. J., Näbauer M., Erdmann E.: Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993; 73: 379-385.
27. Ben-David J., Zipes D.: Alpha adrenoceptor stimulation and blockade modulated cesium-induced early afterdepolariza-tions and ventricular tachyarrhythmias in dogs. Circulation 1990; 82: 225-233.
28. Tan H. L., Hou C.J.Y., Lauer M. R., Sung R. J.: Electrophysiologic mechanism of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122: 701-714.
29. Kohya T., Yokoshiki H., Tohse N., Knno M., Nakaya H., Saito H., Kitabatake A.: Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 1995; 76: 892-899.
30. Neglia D., Parodi O., Gallopin M., Sambuceti G., Giorgetti A., Pratali L., Salvadori P., Michelassi C., Lunardi M., Pelosi G., Marzilli M., L'Abbate A.: Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. Circulation 1995; 92: 796-804.
31. Woo M. A., Stevenson W. G., Moser D. K., Middlekauff H. R.: Complex heart rate variability and serum norepinephrine levels in patients with advanced heart failure. J Am Coll Cardiol 1994; 23: 565-569.
32. Middlekauff H. R., Hamilton M. A., Stevenson W. G., Mark A. L.: Independent control of skin and muscle sympathetic nerve activity in patients with heart failure. Circulation 1994; 90: 1794-1798.
33. Kaye D. M., Lefkovits J., Jennings G. L., Gergin P., Broughton A., Esler M. D.: Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26: 1257-1263.
34. Francis G. S., Cohn J. N., Johnson G., Rector T. S., Goldman S., Simon A.: Plasma norepinephrine, plasma renin activity, and congestive heart failure, relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87: VI40-VI48.
35. Hansen D. E., Borganelli M., Stacy G. P., Taylor L. K.: Dose-dependent inhibition of stretch-induced arrhythmias by gadolinium in isolated canine ventricles. Evidence for a unique mode of antiarrhythmic action. Circ Res 1991; 69: 820-831.
36. Reiter M. J., Synhorst D. P., Mann D. E.: Electrophysiological effects of acute ventricular dilation in the isolated rabbit heart. Circ Res 1988; 62: 554-562.
37. Spear J. F., Moore E. N.: Stretch-induced excitation and conduction disturbances in the isolated rat myocardium. J Electrocardiol 1972; 5: 15-24.
38. Gettes L. S.: Electrolyte abnormalities underlying lethal ventricular arrhythmias. Circulation 1992; 85: 70-76.
39. Chakko S. C., Frutchey J., Gheorghiade M.: Life-threatening hyperkalemia in severe heart failure. Am Heart J 1989; 117:1083-1109.
40. Eichhorn E. J., Tandon P. K., DiBianco R., Timmis G. C., Fenster P. E., Shannon J., Packer M.: Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The PROMISE Study. J Am Coll Cardiol 1993; 21: 634-640.
41. Sueta C. A., Clarke S. W., Dunlap S. H., Jensen L., Blauwet M. B., Koch G., Patterson J. H., Adams KF Jr.: Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. Circulation 1994; 89: 660-666.
42. Gottlieb S. S., Fisher M. L., Pressel M. D., Patten R. D., Weinberg M., Greenberg N.: Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. Am Heart J 1993; 125: 1645-1650.
43. Bashir Y., Sneddon J. F., Staunton A., Haywood G. A., Simpson L. A., McKenna W. J., Camm A. J.: Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1993; 72: 1156-1162.
44. Mason J. W., for the Electrophysiologic Study vs Electrocardiographic Monitoring Investigators: A comparison of electrophysiologic testing with holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmia. JV Engl J Med 1993; 329: 445-451.
45. Pratt C. M., Eaton C. M., Francis M., Woolbert S., Mahmarian J., Roberts R., Young J. B.: The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: A dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118: 433-440.
46. Ravid S., Podrid P. J., Lampert S., Lown B.: Congestive heart failure induced by 6 of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14: 1326-1330.
47. Woosley R. L.: Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am Heart J mi; 114: 1280-1290.
48. Stanton M. S., Prystowsky E. N., Fineberg N. S., Miles W., Zipes D. P., Heger J. J.: Arrhythmogenic effects of antiarrhythmic drugs: A study of 506 patients treated for ventricular tachycardia or fibrillation. J Am Coll Cardiol 1989; 14: 209-215.
49. Packer M.: Hemodynamic consequences of antiarrhythmic drug therapy in patients with chronic congestive heart failure. J Cardiovasc Electrophysiol 1991; 25: 240-247.
50. Falk R. H.: Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141-150.
51. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: CAST mortality and morbidity. Treatment vs placebo. JV Engl J Med 1991; 324: 781-788.
52. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. JV Engl J Med 1992; 327: 227-233.
53. Flaker G. C., Blackshear J. L., McBride R., Kronmal R. A., Halperin J. L., Hart R. G.: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-532.
54. Wagstein F., Bristow M. R., Swedberg K., Camerini F., Fowler M. G., Silver M. A., et al: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342: 1441-1446.
55. Packer M., Bristow M. R., Cohn J. N., Colucci W. S., Fowler M. B., Gilbert E. M., Shusterman N. H.: The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. JV Engl J Med 1996; 334: 1349-1355.
56. Holubarsch C., Schneider R., Pieske B., Ruf T., Hasenfuss G., Fraedrich G., Posival H., Just H.: Positive and negative inotropic effects of dl-sotalol and d-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. Circulation 1995; 92: 2904-2910.
57. Mason J. W.: A comparison of 7 antiarrhythmic drugs in patients with ventricular tachyarrhythmias. JV Engl J Med 1993; 329: 452-458.
58. Waldo A. L., Camm A. J., deRuyter H., Friedman P. L., MacNeil D. J., Pauls J. F., Pitt B., Pratt C. M., Schwartz P. J., Veltri E. P.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Lancet 1996; 348: 7-12.
59. Doval H. C., Nul D. R., Grancelli H. O., Perrone S. V., Bortman G. R., Curiel R.: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-498.
60. Singh S. N., Fletcher R. D., Fisher S. G., Singh B. N., Lewis H. D., Deedwania P. C., Massif B. M., Colling C., Lazzeri D.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. JV Engl J Med 1995; 333: 77-82.
61. Massie B. M., Fisher S. G., Deedwania P. C., Singh B. N., Fletcher R. D., Singh S. N.: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93: 2128-2134.
62. Garguichevich J. J., Ramos J. L., Gambarte A., Gentile A., Hauad S., Scapin O., Sirena J., Tibaldi M., Toplikar J.: Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine pilot study of sudden death and amiodarone (EPAMSA). Am Heart J 1995; 130: 494-500.
63. Zarembski D. G., Nolan P. E., Slack M. K., Caruso A. C.: Empiric long-term amiodarone prophylaxis following myocardial infarction. Arch Intern Med 1993; 153: 2661-2667.
64. Nademanee K., Singh B. N., Stevenson W. G., et al: Amiodarone and post-MI patients. Circulation 1993; 88: 764-774.
65. Riggio D. W., Peters R. W., Feliciano Z., Gottlieb S. S., Shorofsky S. R., Gold M. R.: Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. Am J Cardiol 1995; 75: 1158-1161.
66. Gottlieb S. S., Riggio D. W., Lauria S., Peters R. W., Shorofsky S. R., Cines M., Forman D., Gold M. R.: High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol 1994; 23: 560-564.
67. Ammar A., Wong M., Singh B. N.: Divergent effects of chronic amiodarone administration on systolic and diastolic function in patients with heart disease. Am J Cardiol 1995; 75: 465-469.
68. Nul D. R., Doval H. C., Grancelli H. O., Varini S. D., Soifer S., Perrone S. V., Prieto N., Seapin O.: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997; 29: 1199-1205.
69. Hohnloser S. H., Klingenheben T., Singh B. N.: Amiodarone-associated proarrhythmic effects, A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994; 121: 529-535.
70. Middlekauff H. R., Stevenson W. G., Saxon L. A., Stevenson L. W.: Amiodarone and torsade de pointes in patient with advanced heart failure. Am J Cardiol 1995; 76: 499-501.
71. Chelimsky-Fallick C., Middlekauff H. R., Stevenson W. G., Kobashigawa J., Saxon L. A., Moriguchi J., Brownfield E. D., Hamilton M. A., Drinkwater D., Laks H., Stevenson L. W.: Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol 1992; 20: 1556-1561.
72. Montero J. A., Anguita M., Concha M., Villarrubia A., Garcia J., Arizon J. M., Calleja F., Valles F.: Pacing requirements after orthotopic heart transplantation: Incidence and related factors. J Heart Lung Transplant 1992; 11: 799-802.
73. Jung W., Manz M., Pizzulli L., Pfeiffer D., Llideritz: Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992; 70: 1023-1027.
74. Weinberg B. A., Klein L. S., Bolander J. E., Dusman R. E., Stanton M. S., Heger J. J., Langefeld C., Zipes D. P.: Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109-120.
75. Herre J. M., Sauve M. J., Malone P., Griffin J. C., Helmy I., Lang-berg J. J., Goldberg H., Scheinman M. M.: Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442-449.
76. Dusman R. E., Stanton M. S., Miles W. M., et al: Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51-59.
77. Greenspon A. J., Kidwell G. A., Hurley W., et al: Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991; 84(Suppl III): III-407-UI-415.
78. Figge H. L., Figge J.: The effects of amiodarone on thyroid hormone function: A review of the physiology and clinical manifestations. J Clin Pharmacol 1990; 30: 588-595.
79. Nademanee K., Kannan R., Hendrickson J., Ookhtens M., Kay I., Singh B. N.: Amiodarone-digoxin interaction: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111-116.
80. Heimark L. D., Wienkers L., Kunze K., Gibaldi M., Eddy A. C., Trager W. F., O'Reilly R. A., Goulart D. A.: The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992; 51: 398-407.
81. Strickberger S. A., Brownstein S. L., Wilkoff B. L., Zinner A. J., : Clinical predictors of defibrillation energy requirements in patients treated with a non-throacotomy defibrillator system. Am Heart J 1996; 131: 257-260.
82. Raitt M. H., Johnson G.: Dolack G. L., Poole J. E., Kudenchuk P. J., Bardy G. H.: Clinical predictors of the defibrillation threshold with the unipolar implantable defibrillation system. J Am Coll Cardiol 1995; 25: 1576-1583.
83. Kopp D. E., Blakeman B. P., Kail J. G., Olshansky B., Kinder C. A., Wilber D. J.: Predictors of defibrillation energy requirements with nonepicardial lead systems. Pacing Clin Electrophysiol 1995; 18:253-260.
84. Lucy S. D., Jones D. L., Glein G. J.: Pronounced increase in defibrillation threshold associated with pacing-induced cardiomyopathy in the dog. Am Heart J 1994; 127: 366-376.
85. Bardy G. H., Yee R., Jung W.: Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators. J Am Coll Cardiol 1996; 28: 400-410.
86. Schwartzman D., Concato J., Ren J. F., Callans D. J., Gottlieb C. D., Preminger M. W., Marchlinski F. E.: Factors associated with successful implantation of nonthoracotomy defibrillation lead systems. Am Heart J 1996; 131: 1127-1136.
87. Kim S. G., Roth J. A., Fisher J. D., Chung J., Nagabhairu R., Ferrick K. J., Ben-Zur U., Gross J., Furman S.: Long-term outcomes and modes of death of patients treated with nonthoracotomy implantable defibrillators. Am J Cardiol 1995; 75: 1229-1232.
88. Zipes D. P., Roberts D.: Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. The Pacemaker-Cardioverter-Defibrillator Investigators. Circulation 1995; 92: 59-65.
89. The PCD Investigator Group: Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multipro-grammable implantable cardioverter-defibrillator implanted with or without thoracotomy: An international multicenter study. J Am Coll Cardiol 1994; 23: 1521-1530.
90. Sweeney M. O., Ruskin J. N., Garan H., McGovern B. A., Guy M. L., Torchiana D. F., Vlahakes G. J., Newell J. B., Semigran M. J., Dec G. W.: Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995; 92: 3273-3281.
91. Steinbeck G., Dorwarth U., Mattke S., Hoffmann E., Marke-witz A., Kaulbach H., Tassani P.: Hemodynamic deterioration during ICD implant: Predictors of high-risk patients. Am Heart J 1994; 127: 1064-1067.
92. Jeevanandam V., Bielefeld M. R., Auteri J. S., Sanchez J. A., Schenkel F. A., Michler R. E., Smith C. R., Livelli F., Bigger T. J., Rose E. A., Spotnitz H. M.: The implantable defibrillator: An electronic bridge to cardiac transplantation. Circulation 1992; 86(Suppl II): II276-II279.
93. Kim S. G., Ling J., Fisher J. D., Wang G., Rameneni A., Roth J. A., Ferrick K. J., Gross J., Ben-Zur U., Brodman R., Furman S.: Comparison and frequency of ventricular arrhythmias after defibrillator implantation by thoracotomy vs nonthoracotomy approaches. Am J Cardiol 1994; 74: 1245-1248.
94. Bocker D., Block M., Isbruch F., Weitholt D., Hammel D., Scheld H. H., Borggrefe M., Breithardt G.: Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial vs nonthoracotomy lead systems. Am J Cardiol 1993; 71: 1064-1068.
95. Schwartzman D., Nallamothu N., Callans D. J., Preminger M. W., Gottlieb C. D., Marchlinski F. E.: Postoperative lead-related complications in patients with nonthoracotomy defibrillation lead systems. J Am Coll Cardiol 1995; 26: 776-786.
96. Canceres J., Jazayeri M., McKinnie J.et al: Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989; 79: 256-270.
97. Brugada P., Talajic M., Mffleneers R., Wellens H. J. J.: The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Eur Heart J 1989; 10: 747-752.
98. Meissner M. D., Kay H. R., Horowitz L. N., Spielman S. R., Greenspan A. M., Kutalek S. P.: Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease. Am J Cardiol 1988; 61: 1050-1055.
99. Villacastin J., Almendral J., Arenal A., ALbertos J., Ormaetxe J., Peinado R., Bueno H., Merino J. L., Pastor A., Medina O., Tercedor L., Jimenez F., Decan J. L.: Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation 1996; 93: 753-762.
100. Levine J. H., Mellits E. D., Baumgardner R. A., Veltri E. P., Mower M., Grunwald L., Guarnieri T., Aarons D., Griffith L. S. C.: Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991; 84: 558-566.
101. Saxon L. A., Wiener I., DeLurgio D. B., Natterson P. D., Laks H., Drinkwater D. C., Stevenson W. G.: Implantable defibrillators for high-risk patients with heart failure who are awaiting cardiac transplantation. Am Heart J 1995; 130: 501-506.
102. Kottkamp H., Hindricks G., Chen X., Brunn J., Willems S., Haverkamp W., Block M., Breithardt G., Borggrefe M.: Radiofrequency catheter ablation of sustained ventricular tachycardia in idiopathic dilated cardiomyopathy. Circulation 1995; 92: 1159-1168.
103. Gonska B. D., Cao K., Schaumann A., et al: Catheter ablation of ventricular tachycardia in 136 patients with coronary artery disease: Results and long-term follow-up. J Am Coll Cardiol 1994; 24: 1506-1514.
104. Morady F., Harvey M., Kalbfleisch S. J., et al: Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation 1993; 87: 363-372.
105. Middlekauff H. R., Stevenson W. G., Stevenson L. W., Saxon L. A.: Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21: 110-116.
106. Silverman M. E., Pressel M. D., Brackett J. C., Lauria S. S., Gold M. R., Gottlieb S. S.: Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995; 75: 460-464.
107. Turitto G., Ahuja R. K., Caref E. B., El-Sherif N.: Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: Role of programmed ventricular stimulation and the signal-averaged electrocardiogram. J Am Coll Cardiol 1994; 24: 1523-1528.
108. Yamada T., Fukunami M., Ohmori M., Iwakura K., Kumagai K., Kondoh N., Tsujimura E., Abe Y., Nagareda T., Kotoh K., Hoki N.: New approach to the estimation of the extent of myocardial fibrosis in patients with dilated cardiomyopathy: Use of signal-averaged electrocardiography. Am Heart J 1993; 126: 626-631.
109. Yi G., Keeling P. J., Goldman J. H., Jian H., Poloniecki J., McKenna W. J.: Prognostic significance of spectral turbulence analysis of the signal-averaged electrocardiogram in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1995; 75: 494-497.
110. Denereaz D., Zimmerman M., Adamec R.: Significance of ventricular late potentials in nonischemic dilated cardiomyopathy. Eur Heart J 1992; 14: 895-901.
111. Ohnishi Y., Inoue T., Fukuzaki H.: Value of the signal-averaged electrocardiogram as a predictor of sudden death in myocardial infarction and dilated cardiomyopathy. Jpn Circ J 1990; 54:127-136.
112. Bourke J. P., Richards D.A.B., Ross D. L., Wallace E. M., McGuire M. A., Uther J. B.: Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991; 18: 780-788.
113. Wilber D. J., Olshansky B., Moran J. F., Scanlon P. J.: Electrophysiological testing and nonsustained ventricular tachycardia: Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 1990; 82: 350-358.
114. Moss A. J., Hall W. J., Cannon D. S., et al: Improved survival with an implanted defibrillator in patients at high risk for ventricular arrhythmia. N Engl J Med (in press, 1996).
115. Mahmarian J. J., Smart F. W., Moye L. A., Young J. B., Francis M. J., Kingry C., Verani M. S., Pratt C. M.: Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity. Am J Cardiol 1994; 74: 681-686.